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In this issue of the Journal, Drummond et al. present their report
from the Task Force on Economic Data Transferability [1]. The
ﬁndings and recommendations extend to 11, the number and
scope of guidance documents on contemporary methodology and
policy issues published in Value in Health. These methods guid-
ance documents, representing the intellectual work of leaders in
the ﬁelds of economic evaluation and outcomes research, are
intended to provide analysts with a summary of the pertinent
problems and a clear set of best practice recommendations for
research. The reports receive a great deal of open and often
robust peer review at the ISPOR scientiﬁc meetings and through
an additional formal review by a committee of academic,
government, and industry scientists.
The Task Force considered the rather difﬁcult questions of
whether or not economic data can be transferred from one juris-
diction to another, and if so, under what conditions are the
transferred data valid and useful. This subject has been addressed
in previous publications but not to the extent and detail found in
this report [2,3]. Transferability is of mounting interest because
evolving Health Technology Assessment (HTA) programs are
increasingly requesting localized economic data to support reim-
bursement and pricing decisions. It is simply impossible for spon-
sors of economic studies to undertake de novo research for each
and every jurisdiction. In the instances in which transferability of
economic data is acceptable, guidance as to how to (or not to)
undertake such work has not been available. This report ﬁlls in
this important gap.
Some would suggest, perhaps strongly, that transferability of
economic data is not possible and may lead to wrong conclusions
about the value of a particular technology in a speciﬁc setting.
The argument goes that questions posed by reimbursement
authorities, the health-care systems and beneﬁt packages, com-
parators, treatment strategies, target population characteristics,
and relative prices of health care and labor inputs are so different
as to make transferability unworkable. But, as the authors make
clear, many of these differences can be measured and quantiﬁed
and therefore can be modeled. Additionally, transferability across
jurisdictions can create uncertainty in both model structure and
parameter estimates. But uncertainty can be modeled, too. For
those who support transferability, many of the methods issues
simply reduce to a question of appropriate modeling.
A troubling observation, sadly common to most methods
controversies, emerges from the report. There are few, if any,
well-designed empirical studies directly addressing the speciﬁc
methods issues raised by the Task Force. This fact, although not
the fault of the authors, challenges their ability to make evidence-
based recommendations to researchers.
We should applaud the authors of the Task Force report for
clearly articulating the issues and setting forth recommendations
for making the conduct of transferability of economic data
feasible and more approachable to a wider audience. For juris-
dictions with limited resources wishing to operate technology
assessment programs, transferability may be a reasonable initial
step toward an eventual policy of undertaking their own primary
evidence generation and economic modeling. Nevertheless, and
for reasons well understood by the authors, transferability is
not always possible or even useful, reminding us that we need to
exercise judgment before embarking on such efforts.
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